Dr. Davids on Ibrutinib Plus FCR in Younger Patients With CLL

Matthew S. Davids, MD, MMSc
Published: Friday, Dec 15, 2017



Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in younger patients with chronic lymphocytic leukemia (CLL).

In a study of patients aged 65 or less, ibrutinib is being combined with FCR for up to 6 months, followed by ibrutinib maintenance therapy.

Davids says that many patients in this population like the idea of a combinatorial time-limited approach to treatment, and since they are a fit population, they can undergo a more intensive therapeutic regimen.
 


Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in younger patients with chronic lymphocytic leukemia (CLL).

In a study of patients aged 65 or less, ibrutinib is being combined with FCR for up to 6 months, followed by ibrutinib maintenance therapy.

Davids says that many patients in this population like the idea of a combinatorial time-limited approach to treatment, and since they are a fit population, they can undergo a more intensive therapeutic regimen.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x